Shares of Tactile Systems Technology (TCMD) have gained 3.4% over the past four weeks to close the last trading session at $29.61, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $38 indicates a potential upside of 28.3%.The mean estimate comprises four short-term price targets with a standard deviation of $4.32. While the lowest estimate of $32.00 indicates an 8.1% increase fro ...

On February 19, Joseph Stiglitz, the Nobel Prize-winning economist and ‘The Road to Freedom’ author, joined CNBC’s ‘Squawk Box’ to discuss the state of the economy and argued that conditions are poor and likely to deteriorate. Challenging more optimistic views, Stiglitz addressed the debate over why tariffs have not sparked an immediate inflationary explosion. He explained that economists must consider the counterfactual: what inflation would have been without the tariffs. He noted that while inflation was ...

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying the right ones involves navigating significant risks and volatility [1] Group 1: Company Overview - Tactile Systems Technology (TCMD) is currently highlighted as a recommended growth stock by the Zacks Growth Style Score system, which evaluates a company's genuine growth potential [2] - The company holds a favorable Growth Score and a top Zacks Rank, indicating strong investment potential [2] Group 2: Earnings Growth - Tactile Systems Technology has a historical EPS growth rate of 17.9%, but the projected EPS growth for this year is significantly higher at 38.6%, surpassing the industry average of 10.4% [4] Group 3: Asset Utilization - The company's asset utilization ratio (sales-to-total-assets ratio) is 1.21, indicating that it generates $1.21 in sales for every dollar in assets, which is notably higher than the industry average of 0.6 [6] - Tactile Systems Technology's sales are expected to grow by 9.1% this year, compared to the industry average of 8.7% [6] Group 4: Earnings Estimate Revisions - The current-year earnings estimates for Tactile Systems Technology have been revised upward, with the Zacks Consensus Estimate increasing by 17.6% over the past month, reflecting a positive trend in earnings estimate revisions [7] Group 5: Investment Positioning - Tactile Systems Technology has achieved a Zacks Rank of 2 (Buy) and a Growth Score of B, positioning it favorably for potential outperformance in the growth stock category [9]

Tactile Systems reported fourth-quarter earnings of 46 cents, better than the consensus of 44 cents. Sales jumped 21% to $103.59 million, beating the Wall Street estimates of $93.80 million, attributable to lymphedema and airway clearance product lines.Tactile Systems forecasts fiscal 2026 sales between $357 million-$365 million compared to the consensus of $347.94 million. The company expects adjusted EBITDA in the range of $49 million to $51 million.Tactile Systems shares fell 5.3% to close at $283.46 on ...

Tactile Systems reported fourth-quarter earnings of 46 cents, better than the consensus of 44 cents. Sales jumped 21% to $103.59 million, beating the Wall Street estimates of $93.80 million, attributable to lymphedema and airway clearance product lines.Tactile Systems forecasts fiscal 2026 sales between $357 million-$365 million compared to the consensus of $347.94 million. The company expects adjusted EBITDA in the range of $49 million to $51 million.Tactile Systems shares fell 5.3% to close at $283.46 on ...

Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.4 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.77%. A quarter ago, it was expected that this medical device maker would post earnings of $0.16 per share when it actually produced earnings of $0.36, delivering a surprise of +125%.Over the last four ...

Tactile Systems (NasdaqGM:TCMD) Q4 2025 Earnings call February 17, 2026 05:00 PM ET Company ParticipantsBen Haynor - Managing DirectorElaine Birkemeyer - CFOKyle Winborne - Equity ResearchSam Benzinger - Investor RelationsSheri Dodd - CEOConference Call ParticipantsBrandon Vasquez - Research AnalystNone - AnalystOperatorPlease stand by. Welcome, ladies and gentlemen, to the fourth quarter and full year 2025 earnings conference call for Tactile Medical. At this time, all participants have been placed in list ...

Financial Data and Key Metrics Changes - Total revenue for the full year 2025 was $329.5 million, a 12% increase year-over-year [4] - Adjusted EBITDA increased 21% year-over-year to $44.8 million [5] - Q4 revenue grew by 21% year-over-year to $103.6 million [29] - Gross margin for Q4 was 78.2%, up from 75.2% in Q4 2024 [29] - Net income increased 9% to $10.6 million, or $0.46 per diluted share [31] Business Line Data and Key Metrics Changes - Lymphedema revenue increased 16% year-over-year to $89.5 million in Q4 [6] - Airway clearance revenue increased 66% year-over-year to $14.1 million in Q4 [6] - For 2026, total revenue is expected to be in the range of $357 million to $365 million, representing year-over-year growth of 8% to 11% [6][32] Market Data and Key Metrics Changes - The Medicare channel remained strong in Q4, with patients moving directly to the Flexitouch Advanced pump under new NCD criteria [11] - The company expects a temporary short-term impact from the new Medicare prior authorization requirement for pneumatic compression devices [32][34] Company Strategy and Development Direction - The acquisition of LymphaTech is seen as a milestone in evolving from a product-based company to a comprehensive integrated solutions leader for lymphatic dysfunction [15][17] - Strategic priorities include improving access to care, expanding treatment options, and enhancing lifetime patient value [8][25] - The company plans to leverage AI-enabled technology to improve order processes and operational efficiency [21][22] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the new Medicare prior authorization requirements and expects to maintain growth in line with the overall lymphedema market [34][36] - The company is optimistic about the integration of LymphaTech and its potential to enhance patient care and streamline clinical workflows [15][53] Other Important Information - The company ended 2025 with $83.4 million in cash and cash equivalents and no outstanding borrowings [31] - The company repaid the full outstanding principal balance of $26.3 million on its term loan and repurchased $26.5 million of its stock [5] Q&A Session Summary Question: What drove the strong performance in the Lymphedema business in Q4? - Management noted multiple investments in people, processes, and technology, including strong CRM adoption and increased sales rep productivity [41] Question: How do the new prior authorization requirements balance with the tailwinds from the NCD? - Management indicated that the guidance reflects a balanced approach, incorporating both tailwinds from the NCD and the headwinds from prior authorization [44][45] Question: Can you elaborate on the LymphaTech acquisition and its commercialization model? - Management expressed excitement about integrating LymphaTech into their commercial engine and highlighted its potential for improving patient experience and workflow efficiency [51][53] Question: What are the expectations for EBITDA margins moving forward? - Management indicated that while EBITDA margins are expected to grow modestly, they anticipate further expansion in the long term as investments are annualized [66]

Financial Data and Key Metrics Changes - Total revenue for the full year 2025 was $329.5 million, a 12% increase year-over-year [4] - Full year gross margins expanded by 190 basis points year-over-year to 75.9% [5] - Adjusted EBITDA increased 21% year-over-year to $44.8 million [5] - Q4 total revenue grew by 21% year-over-year to $103.6 million [28] - Q4 gross margin was 78.2%, compared to 75.2% in Q4 2024 [28] - Net income increased by 9% to $10.6 million, or $0.46 per diluted share [30] Business Line Data and Key Metrics Changes - Lymphedema revenue increased 16% year-over-year to $89.5 million in Q4 [6] - Airway clearance revenue increased 66% year-over-year to $14.1 million in Q4 [6] - Sales and rentals of lymphedema products increased by $12.4 million, or 16% [28] - Sales of airway clearance products increased by $5.6 million, or 66% [28] Market Data and Key Metrics Changes - The company expects total revenue for 2026 to be in the range of $357 million to $365 million, representing year-over-year growth of 8% to 11% [6][31] - The Medicare channel remained strong in Q4, with patients moving directly to the Flexitouch Advanced pump under new NCD criteria [10] Company Strategy and Development Direction - The acquisition of LymphaTech is a significant milestone, expanding the company's capabilities in lymphedema solutions and enhancing R&D [8][15] - Strategic priorities include improving access to care, expanding treatment options, and enhancing lifetime patient value [9][25] - The company aims to leverage AI technology to improve order processes and operational efficiency [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the new Medicare prior authorization requirements, viewing them as a short-term headwind [31][46] - The company believes it is well-positioned to continue delivering growth in line with the overall lymphedema market [33] - Management highlighted the importance of ongoing investments in people and technology to support future growth [37] Other Important Information - The company ended 2025 with $83.4 million in cash and cash equivalents and generated close to $43 million in operating cash flow during the year [5] - The company has no outstanding borrowings as of the end of Q4 2025 [30] Q&A Session Summary Question: What drove the strong performance in the lymphedema business in Q4? - Management noted multiple investments in people, processes, and technology, including strong CRM adoption and increased sales rep productivity [41][42] Question: How do the new prior authorization requirements balance with the tailwinds from the NCD? - Management indicated that the guidance reflects a balanced approach, incorporating both tailwinds from the NCD and the headwinds from prior authorization [44][46] Question: Can you elaborate on the LymphaTech acquisition and its commercialization model? - Management expressed excitement about integrating LymphaTech into their commercial engine, focusing on measurement and surveillance for lymphedema [53][55] Question: What are the expectations for EBITDA margin growth moving forward? - Management indicated that while EBITDA margins are expected to grow modestly in 2026, long-term growth is anticipated as investments are completed [68]

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR 3701 Wayzata Blvd, Suite 300 Minneapolis, Minnesota 55416 (Address and zip code of principal executive offices) 41-1801204 (I.R.S. Employer Id ...